Monte Rosa Therapeutics (GLUE) Total Liabilities (2023 - 2025)
Historic Total Liabilities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $214.0 million.
- Monte Rosa Therapeutics' Total Liabilities rose 9521.82% to $214.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.0 million, marking a year-over-year increase of 9521.82%. This contributed to the annual value of $215.8 million for FY2024, which is 7332.32% up from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Total Liabilities is $214.0 million, which was up 9521.82% from $91.5 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Total Liabilities ranged from a high of $215.8 million in Q4 2024 and a low of $65.0 million during Q2 2023
- In the last 3 years, Monte Rosa Therapeutics' Total Liabilities had a median value of $114.2 million in 2024 and averaged $118.6 million.
- Over the last 5 years, Monte Rosa Therapeutics' Total Liabilities had its largest YoY gain of 9521.82% in 2025, and its largest YoY loss of 2338.94% in 2025.
- Monte Rosa Therapeutics' Total Liabilities (Quarter) stood at $124.5 million in 2023, then soared by 73.32% to $215.8 million in 2024, then fell by 0.83% to $214.0 million in 2025.
- Its last three reported values are $214.0 million in Q3 2025, $91.5 million for Q2 2025, and $118.0 million during Q1 2025.